For the quarter ending 2025-12-31, CVM had -$4,675,878 decrease in cash & cash equivalents over the period. -$4,022,105 in free cash flow.
| Cash Flow | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| Net loss | -5,469,446 | 25,411,055 | - |
| Depreciation and amortization | 964,422 | 960,850 | 2,924,303 |
| Net loss | - | - | -19,310,155 |
| Non-cash lease expense, net of lease payments | -2,301 | 2,842 | 2,970 |
| Share-based payments for services | 58,318 | 167,388 | 587,285 |
| Equity based compensation | 443,275 | 440,506 | 1,470,491 |
| Common stock contributed to 401 plan | 57,262 | 53,807 | 164,510 |
| Shares issued for settlement of clinic development costs | 48,127 | 0 | 350,885 |
| Loss on patent impairment | 12,851 | 4,963 | 13,312 |
| Prepaid expenses | 183,258 | 28,676 | 13,874 |
| Supplies used for r&d and manufacturing | -55,677 | -350,834 | -622,831 |
| Deposits | 0 | 7,585 | -4,000 |
| Accounts payable | 71,171 | -445,154 | 2,444 |
| Accrued expenses | -226,360 | 181,218 | -60,490 |
| Due to employees | 143,555 | -252,932 | 806,214 |
| Proceeds from related party loans | - | 0 | - |
| Net cash used in operating activities | -4,022,105 | -4,670,523 | -12,449,214 |
| Payments of related party loans | - | 0 | - |
| Purchases of property and equipment | 0 | 5,155 | 32,954 |
| Proceeds from notes payable | - | 0 | 350,000 |
| Expenditures for patent costs | - | 0 | 0 |
| Proceeds from the purchase of stock by officers and directors | - | - | 0 |
| Net cash used in investing activities | 0 | -5,155 | -32,954 |
| Proceeds from issuance of common stock and pre-funded warrants | 0 | 15,730,800 | 12,560,300 |
| Payments of stock issuance costs | 158,115 | 1,594,947 | 1,531,832 |
| Payments of notes payable | - | 0 | 350,000 |
| Proceeds from the purchase of stock by officers and directors | 49,999 | -219,995 | - |
| Payments on obligations under finance leases | 545,657 | 519,566 | 1,491,617 |
| Net cash (used in) provided by financing activities | -653,773 | 13,836,282 | 9,536,851 |
| Net decrease in cash and cash equivalents | -4,675,878 | 9,160,604 | -2,945,317 |
| Cash and cash equivalents at beginning of period | 10,953,460 | 4,738,173 | - |
| Cash and cash equivalents at end of period | 6,277,582 | 10,953,460 | - |
CEL SCI CORP (CVM)
CEL SCI CORP (CVM)